These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 19521959

  • 1. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel.
    Sauer L, Nunes J, Salunkhe V, Skalska L, Kohama T, Cuvillier O, Waxman J, Pchejetski D.
    Int J Cancer; 2009 Dec 01; 125(11):2728-36. PubMed ID: 19521959
    [Abstract] [Full Text] [Related]

  • 2. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.
    Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissié J, Malavaud B, Cuvillier O.
    Cancer Res; 2005 Dec 15; 65(24):11667-75. PubMed ID: 16357178
    [Abstract] [Full Text] [Related]

  • 3. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
    Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman J, Cuvillier O.
    Cancer Res; 2010 Nov 01; 70(21):8651-61. PubMed ID: 20959468
    [Abstract] [Full Text] [Related]

  • 4. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.
    Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, Waxman J, Malavaud B, Cuvillier O.
    Mol Cancer Ther; 2008 Jul 01; 7(7):1836-45. PubMed ID: 18644996
    [Abstract] [Full Text] [Related]

  • 5. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME.
    Int J Cancer; 2008 May 15; 122(10):2368-76. PubMed ID: 18240145
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
    Sakai I, Miyake H, Terakawa T, Fujisawa M.
    Cancer Sci; 2011 Apr 15; 102(4):769-75. PubMed ID: 21214673
    [Abstract] [Full Text] [Related]

  • 7. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Naito R, Kano H, Shimada T, Makino T, Kadomoto S, Iwamoto H, Yaegashi H, Izumi K, Kadono Y, Nakata H, Saito Y, Goto M, Nakagawa-Goto K, Mizokami A.
    Prostate; 2021 Apr 15; 81(5):295-306. PubMed ID: 33493355
    [Abstract] [Full Text] [Related]

  • 8. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation.
    Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, Igarashi Y, Nozawa Y.
    Biochem Biophys Res Commun; 2006 Apr 21; 342(4):1284-90. PubMed ID: 16516161
    [Abstract] [Full Text] [Related]

  • 9. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
    Benelli R, Monteghirfo S, Balbi C, Barboro P, Ferrari N.
    Int J Cancer; 2009 Jun 15; 124(12):2989-96. PubMed ID: 19319982
    [Abstract] [Full Text] [Related]

  • 10. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
    Luo Y, Ling Y, Guo W, Pang J, Liu W, Fang Y, Wen X, Wei K, Gao X.
    J Control Release; 2010 Oct 15; 147(2):278-88. PubMed ID: 20655966
    [Abstract] [Full Text] [Related]

  • 11. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
    Gravina GL, Marampon F, Petini F, Biordi L, Sherris D, Jannini EA, Tombolini V, Festuccia C.
    Endocr Relat Cancer; 2011 Aug 15; 18(4):385-400. PubMed ID: 21551258
    [Abstract] [Full Text] [Related]

  • 12. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
    Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK.
    Int J Cancer; 2007 Jan 01; 120(1):160-9. PubMed ID: 17013895
    [Abstract] [Full Text] [Related]

  • 13. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B.
    Clin Cancer Res; 2006 Sep 15; 12(18):5578-86. PubMed ID: 17000695
    [Abstract] [Full Text] [Related]

  • 14. [Role of SPHK1 regulates multi-drug resistance of small cell lung cancer 
and its clinical significance].
    Yang L, Hu H, Deng Y, Bai Y.
    Zhongguo Fei Ai Za Zhi; 2014 Nov 15; 17(11):769-77. PubMed ID: 25404266
    [Abstract] [Full Text] [Related]

  • 15. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Liu G, Taylor SA, Marrinan CH, Hsieh Y, Bishop WR, Kirschmeier P, Long BJ.
    Int J Cancer; 2009 Dec 01; 125(11):2711-20. PubMed ID: 19530253
    [Abstract] [Full Text] [Related]

  • 16. Bioactive sphingolipids in docetaxel-induced apoptosis in human prostate cancer cells.
    Bassoy EY, Baran Y.
    Biomed Pharmacother; 2012 Mar 01; 66(2):103-10. PubMed ID: 22326625
    [Abstract] [Full Text] [Related]

  • 17. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME.
    BJU Int; 2008 Aug 01; 102(3):389-97. PubMed ID: 18336596
    [Abstract] [Full Text] [Related]

  • 18. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J, Liu W, Fan YZ, He DL, Li L.
    Theranostics; 2018 Aug 01; 8(1):109-123. PubMed ID: 29290796
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.